PL03.01. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-year Overall Survival Landmark Update

Monday, September 14, 2026 8:17 AM to 8:27 AM · 10 min. (Asia/Seoul)

Join the event!

See all the content and easy-to-use features by logging in or registering!